Torthaí cuardaigh údar

1

Retrograde Cricopharyngeus Dysfunction, a New Motility Disorder: Single Center Case Series and Treatment Results de réir Stijn Arnaert, Joris Arts, Karlien Raymenants, Filip Baert, Kathelijne Delsupehe

Foilsithe / Cruthaithe 2024

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
2

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice de réir Cathérine Reenaers, Peter Bossuyt, P. Hindryckx, Hilde Vanpoucke, Anneline Cremer, Filip Baert

Foilsithe / Cruthaithe 2018

Faigh an téacs iomlán
Revisão

Cuir le mo chuid Ceanán

Sábháilte in:
3

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum de réir Geert D’Haens, Karel Geboes, Marc Peeters, Filip Baert, Freddy Penninckx, P. Rutgeerts

Foilsithe / Cruthaithe 1998

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
4

Clinical Trials in Ulcerative Colitis: A Historical Perspective de réir Pieter Hindryckx, Filip Baert, Ailsa Hart, Fernando Magro, Alessandro Armuzzi, Laurent Peyrin–Biroulet

Foilsithe / Cruthaithe 2015

Faigh an téacs iomlán Faigh an téacs iomlán
Revisão

Cuir le mo chuid Ceanán

Sábháilte in:
5

Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics de réir Marc Peeters, Hilde Nevens, Filip Baert, Martin Hiele, A Meyer, Robert Vlietinck, P. Rutgeerts

Foilsithe / Cruthaithe 1996

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
6

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease de réir Séverine Vermeire, M. Noman, Gert Van Assche, Filip Baert, Geert D’Haens, P. Rutgeerts

Foilsithe / Cruthaithe 2007

Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
7

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease de réir Filip Baert, Maja Noman, Séverine Vermeire, Gert Van Assche, Geert D' Haens, An Carbonez, Paul Rutgeerts

Foilsithe / Cruthaithe 2003

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
8

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis de réir Konstantinos Papamichael, Filip Baert, Sophie Tops, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Ann Gils, Marc Ferrante

Foilsithe / Cruthaithe 2016

Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
9

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy de réir Filip Baert, David Drobne, Ann Gils, Niels Vande Casteele, Scott Hauenstein, Sharat Singh, S. Lockton, Paul Rutgeerts, Séverine Vermeire

Foilsithe / Cruthaithe 2014

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
10

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis de réir Filip Baert, Niels Vande Casteele, Anita Bengtsson Tops, Maja Noman, Gert Van Assche, P. Rutgeerts, Ann Gils, Séverine Vermeire, Marc Ferrante

Foilsithe / Cruthaithe 2014

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
11

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients de réir Filip Baert, E Glorieus, Cathérine Reenaers, Geert D’Haens, Harald Peeters, D Franchimont, Olivier Dewit, Philippe Caenepeel, Édouard Louis, Gert Van Assche

Foilsithe / Cruthaithe 2012

Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
12

Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis de réir Filip Baert, Karel Wouters, Geert D’Haens, P Hoang, Serge Naegels, F D’Heygere, J Holvoet, E Louis, Martine Devos, Karel Geboes

Foilsithe / Cruthaithe 1999

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
13

$Efficacy of infliximab in refractory pouchitis and Crohnʼs disease-related complications of the pouch: A Belgian case series$

Efficacy of infliximab in refractory pouchitis and Crohnʼs disease-related complications of the pouch: A Belgian case series de réir Marc Ferrante, Geert D’Haens, Olivier Dewit, Filip Baert, Jan Holvoet, Karel Geboes, Gert De Hertogh, Gert Van Assche, Séverine Vermeire, Paul Rutgeerts

Foilsithe / Cruthaithe 2009

Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
14

Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial de réir Geert D’Haens, Sander van Deventer, Ruud van Hogezand, Douglas M. Chalmers, C Kothe, Filip Baert, Tanja Braakman, T Schaible, Karel Geboes, Paul Rutgeerts

Foilsithe / Cruthaithe 1999

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
15

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial de réir Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens, Filip Baert, Maja Noman, Séverine Vermeire, David Ternant, Hervé Watier, Gilles Paintaud, Paul Rutgeerts

Foilsithe / Cruthaithe 2008

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
16

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study de réir Séverine Vermeire, F D’Heygere, A. Nakad, Denis Franchimont, Fernand Fontaine, Édouard Louis, Philippe Van Hootegem, Olivier Dewit, Guy Lambrecht, Beatrijs Strubbe, Filip Baert

Foilsithe / Cruthaithe 2018

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
17

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease de réir Filip Baert, Liesbeth Moortgat, Gert Van Assche, Philip Caenepeel, Philippe Vergauwe, Martine De Vos, Pieter Stokkers, Daniël W. Hommes, Paul Rutgeerts, Séverine Vermeire, Geert D’Haens

Foilsithe / Cruthaithe 2009

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
18

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis de réir William J. Sandborn, Filip Baert, Silvio Danese, Željko Krznarić, Taku Kobayashi, Xiaopan Yao, Jingjing Chen, Maria Rosario, Siddharth Bhatia, Krisztina Kisfalvi, Geert D’Haens, Séverine Vermeire

Foilsithe / Cruthaithe 2019

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
19

Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas de réir Nancy Van Damme, Philippe Deron, Nadine Van Roy, Pieter Demetter, Alain Bols, Jo Van Dorpe, Filip Baert, Jean–Luc Van Laethem, Frank Speleman, Patrick Pauwels, Marc Peeters

Foilsithe / Cruthaithe 2010

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
20

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease de réir Geert D’Haens, Marc Ferrante, Séverine Vermeire, Filip Baert, Maja Noman, Liesbeth Moortgat, Patricia Geens, Doreen Iwens, Isolde Aerden, Gert Van Assche, Gust Van Olmen, Paul Rutgeerts

Foilsithe / Cruthaithe 2012

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:

Torthaí cuardaigh - Filip Baert

Retrograde Cricopharyngeus Dysfunction, a New Motility Disorder: Single Center Case Series and Treatment Results de réir Stijn Arnaert, Joris Arts, Karlien Raymenants, Filip Baert, Kathelijne Delsupehe

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice de réir Cathérine Reenaers, Peter Bossuyt, P. Hindryckx, Hilde Vanpoucke, Anneline Cremer, Filip Baert

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum de réir Geert D’Haens, Karel Geboes, Marc Peeters, Filip Baert, Freddy Penninckx, P. Rutgeerts

Clinical Trials in Ulcerative Colitis: A Historical Perspective de réir Pieter Hindryckx, Filip Baert, Ailsa Hart, Fernando Magro, Alessandro Armuzzi, Laurent Peyrin–Biroulet

Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics de réir Marc Peeters, Hilde Nevens, Filip Baert, Martin Hiele, A Meyer, Robert Vlietinck, P. Rutgeerts

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease de réir Séverine Vermeire, M. Noman, Gert Van Assche, Filip Baert, Geert D’Haens, P. Rutgeerts

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease de réir Filip Baert, Maja Noman, Séverine Vermeire, Gert Van Assche, Geert D' Haens, An Carbonez, Paul Rutgeerts

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis de réir Konstantinos Papamichael, Filip Baert, Sophie Tops, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Ann Gils, Marc Ferrante

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy de réir Filip Baert, David Drobne, Ann Gils, Niels Vande Casteele, Scott Hauenstein, Sharat Singh, S. Lockton, Paul Rutgeerts, Séverine Vermeire

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis de réir Filip Baert, Niels Vande Casteele, Anita Bengtsson Tops, Maja Noman, Gert Van Assche, P. Rutgeerts, Ann Gils, Séverine Vermeire, Marc Ferrante

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients de réir Filip Baert, E Glorieus, Cathérine Reenaers, Geert D’Haens, Harald Peeters, D Franchimont, Olivier Dewit, Philippe Caenepeel, Édouard Louis, Gert Van Assche

Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis de réir Filip Baert, Karel Wouters, Geert D’Haens, P Hoang, Serge Naegels, F D’Heygere, J Holvoet, E Louis, Martine Devos, Karel Geboes

Efficacy of infliximab in refractory pouchitis and Crohnʼs disease-related complications of the pouch: A Belgian case series de réir Marc Ferrante, Geert D’Haens, Olivier Dewit, Filip Baert, Jan Holvoet, Karel Geboes, Gert De Hertogh, Gert Van Assche, Séverine Vermeire, Paul Rutgeerts

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial de réir Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens, Filip Baert, Maja Noman, Séverine Vermeire, David Ternant, Hervé Watier, Gilles Paintaud, Paul Rutgeerts

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease de réir Filip Baert, Liesbeth Moortgat, Gert Van Assche, Philip Caenepeel, Philippe Vergauwe, Martine De Vos, Pieter Stokkers, Daniël W. Hommes, Paul Rutgeerts, Séverine Vermeire, Geert D’Haens

Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas de réir Nancy Van Damme, Philippe Deron, Nadine Van Roy, Pieter Demetter, Alain Bols, Jo Van Dorpe, Filip Baert, Jean–Luc Van Laethem, Frank Speleman, Patrick Pauwels, Marc Peeters

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease de réir Geert D’Haens, Marc Ferrante, Séverine Vermeire, Filip Baert, Maja Noman, Liesbeth Moortgat, Patricia Geens, Doreen Iwens, Isolde Aerden, Gert Van Assche, Gust Van Olmen, Paul Rutgeerts

Uirlisí cuardaigh:

Ábhair a bhaineann le hábhar